Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA's Medical Literature Monitoring Service Creates New Complexities For Pharma

This article was originally published in SRA

Executive Summary

Several drug companies are struggling to align their processes with the European Medicines Agency's new medical literature monitoring (MLM) service that was launched earlier this year to reduce the administrative burden associated with monitoring and reporting of suspected adverse reactions from drugs containing certain active substances1,2.


Related Content

Roadmap On Improvements To EMA's Literature Monitoring Service Due By Year End
EMA Tackles Complexities Introduced By Literature Monitoring Service



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts